Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Amg-900. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AURKA known ✓ | O14965 | 4/20 | 1.00 |
| ▸ | AURKB known ✓ | Q96GD4 | 3/20 | 1.00 |
| ▸ | AURKC known ✓ | Q9UQB9 | 1/20 | 1.00 |
| ▸ | ULK1 | O75385 | 1/20 | 1.00 |
| ▸ | RPS6KA5 | O75582 | 1/20 | 1.00 |
| ▸ | RPS6KA4 | O75676 | 1/20 | 1.00 |
| ▸ | PRKD3 | O94806 | 1/20 | 1.00 |
| ▸ | ABL1 | P00519 | 1/20 | 1.00 |
| ▸ | FES | P07332 | 1/20 | 1.00 |
| ▸ | RET | P07949 | 1/20 | 1.00 |
| ▸ | BCR | P11274 | 1/20 | 1.00 |
| ▸ | BRAF | P15056 | 1/20 | 1.00 |
| ▸ | NQO2 | P16083 | 1/20 | 1.00 |
| ▸ | MAP2K2 | P36507 | 1/20 | 1.00 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 1.00 |
| ▸ | CLK1 | P49759 | 1/20 | 1.00 |
| ▸ | CLK2 | P49760 | 1/20 | 1.00 |
| ▸ | CLK3 | P49761 | 1/20 | 1.00 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 1.00 |
| ▸ | TOP2B | Q02880 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Amg-900 SCHEMBL29479191 | 1.00 | AURKA (1.00) | AURKAAURKBULK1RPS6KA5RPS6KA4 | |
| Amg-900 SCHEMBL503564 | 1.00 | AURKA (1.00) | AURKAAURKBULK1RPS6KA5RPS6KA4 | |
| SCHEMBL581178 | 0.92 | AURKB (0.84) | AURKAAURKBULK1RPS6KA5RPS6KA4 | |
| SCHEMBL580354 | 0.91 | AURKA (0.84) | AURKAAURKBULK1RPS6KA5RPS6KA4 | |
| SCHEMBL581542 | 0.90 | AURKA (0.82) | AURKAAURKBULK1RPS6KA5RPS6KA4 | |
| SCHEMBL581159 | 0.90 | AURKB (0.81) | AURKAAURKBULK1RPS6KA5RPS6KA4 | |
| SCHEMBL16290183 | 0.90 | AURKA (0.81) | AURKAAURKBULK1RPS6KA5RPS6KA4 | |
| SCHEMBL580342 | 0.89 | AURKA (0.80) | AURKAAURKBULK1RPS6KA5RPS6KA4 | |
| SCHEMBL580667 | 0.88 | AURKA (0.78) | AURKAAURKBULK1RPS6KA5RPS6KA4 | |
| SCHEMBL580529 | 0.88 | AURKA (0.78) | AURKAAURKBULK1RPS6KA5RPS6KA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 524 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4048260-B1 | COMBINATION OF SUBSTITUTED 4-AMINOISOINDOLINE-1,3-DIONE COMPOUNDS AND SECOND ACTIVE AGENTS FOR USE IN TREATING A HEMATOLOGICAL MALIGNANCY | CELGENE CORP (US) | 2026-03-11 | — | — | EP | claimed |
| EP-4667458-A1 | PHARMACEUTICAL COMPOSITION FOR TREATMENT OF CANCER, COMPRISING SOS1 INHIBITOR AND ANTICANCER DRUG | Kanaph Therapeutics Inc. (KR) | 2025-12-24 | — | — | EP | claimed |
| US-20250352551-A1 | SUBSTITUTED 4-AMINOISOINDOLINE-1,3-DIONE COMPOUNDS AND SECOND ACTIVE AGENTS FOR COMBINED USE | CELGENE CORPORATION | 2025-11-20 | — | — | US | claimed |
| EP-4640238-A1 | THERAPEUTIC AGENT FOR PULMONARY DISEASE, HEPATIC DISEASE OR RENAL DISEASE, WHICH CONTAINS PGAM-CHK1 BINDING INHIBITOR | Kyoto University (JP) | 2025-10-29 | — | — | EP | claimed |
| US-12419900-B2 | Induction of synthetic lethality with epigenetic therapy | THE JOHNS HOPKINS UNIVERSITY (US) | 2025-09-23 | — | — | US | claimed |
| US-12396995-B2 | Substituted 4-aminoisoindoline-1,3-dione compounds and second active agents for combined use | CELGENE CORPORATION (US) | 2025-08-26 | — | — | US | claimed |
| WO-2025101836-A1 | METHOD FOR INDUCING ANEUPLOIDY AND/OR CHROMOSOMAL INSTABILITY IN HUMAN OR NON-HUMAN PRIMATE PLURIPOTENT STEM CELLS AND DIAGNOSTIC/THERAPEUTIC USES THEREOF | THE TRUSTEES OF DARTMOUTH COLLEGE (US) | 2025-05-15 | — | — | WO | claimed |
| US-20250146080-A1 | METHODS FOR OVERCOMING TAZEMETOSTAT-RESISTANCE IN CANCER PATIENTS | MEMORIAL SLOAN KETTERING CANCER CENTER (US) | 2025-05-08 | — | — | US | claimed |
| WO-2025074271-A1 | MYT1 INHIBITORS FOR THE TREATMENT OF CANCERS HARBORING REPLICATION STRESS MUTATIONS | REPARE THERAPEUTICS INC. (CA) | 2025-04-10 | — | — | WO | claimed |
| US-20250003952-A1 | SENOLYTIC DRUG SCREENING METHOD AND SENOLYTIC DRUG | KYOTO UNIVERSITY (JP) | 2025-01-02 | — | — | US | claimed |
| US-20230100402-A1 | INDUCTION OF SYNTHETIC LETHALITY WITH EPIGENETIC THERAPY | THE JOHNS HOPKINS UNIVERSITY | 2023-03-30 | — | — | US | claimed |
| WO-2023038027-A1 | SENOLYTIC DRUG SCREENING METHOD AND SENOLYTIC DRUG | 国立大学法人京都大学 | 2023-03-16 | — | — | WO | claimed |
| WO-2022217073-A1 | METHODS FOR INHIBITING KRAS ONCOPROTEIN THROUGH ENHANCED GTPASE ACTIVITY | MEMORIAL SLOAN-KETTERING CANCER CENTER (US) | 2022-10-13 | — | — | WO | claimed |
| WO-2022213204-A1 | COMBINATION THERAPIES INCLUDING MYT1 INHIBITORS | REPARE THERAPEUTICS INC. (CA) | 2022-10-13 | — | — | WO | claimed |
| WO-2022192139-A1 | AURORA KINASE B INHIBITORS FOR USE FOR TREATING CANCER | ASTRAZENECA AB (SE) | 2022-09-15 | — | — | WO | claimed |
| US-20220280484-A1 | NOVEL USE | IMPERIAL COLLEGE INNOVATIONS LIMITED (GB) | 2022-09-08 | — | — | US | claimed |
| EP-4048260-A1 | SUBSTITUTED 4-AMINOISOINDOLINE-1,3-DIONE COMPOUNDS AND SECOND ACTIVE AGENTS FOR COMBINED USE | Celgene Corporation (US) | 2022-08-31 | — | — | EP | claimed |
| WO-2022104097-A2 | MK2 ACTIVATING COMPOUNDS FOR USE IN TREATING VASCULAR LEAK AND ENDOTHELIAL BARRIER DISORDERS | AKTTYVA THERAPEUTICS, INC. (US) | 2022-05-19 | — | — | WO | claimed |
| WO-2022090746-A1 | NMT INHIBITORS FOR TREATING SENESCENCE-ASSOCIATED DISEASES OR DISORDERS | IMPERIAL COLLEGE INNOVATIONS LIMITED (GB) | 2022-05-05 | — | — | WO | claimed |
| US-11298422-B2 | Treating tumors with TTFields and an aurora kinase inhibitor | NOVOCURE GMBH (CH) | 2022-04-12 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230100402-A1 | INDUCTION OF SYNTHETIC LETHALITY WITH EPIGENETIC THERAPY | MCL1, BAD, ACIN1 | AURKA 2005/4885AURKB 733/4885AURKC 776/4885 |
| US-20250352551-A1 | SUBSTITUTED 4-AMINOISOINDOLINE-1,3-DIONE COMPOUNDS AND SECOND ACTIVE AGENTS FOR COMBINED USE | DOT1L, CARM1, EZH2 | AURKA 249/4885AURKB 320/4885AURKC 313/4885 |
| US-12396995-B2 | Substituted 4-aminoisoindoline-1,3-dione compounds and second active agents for combined use | DOT1L, CARM1, EZH2 | AURKA 249/4885AURKB 320/4885AURKC 313/4885 |
| US-12419900-B2 | Induction of synthetic lethality with epigenetic therapy | MCL1, BAD, ACIN1 | AURKA 2005/4885AURKB 733/4885AURKC 776/4885 |
| US-20220280484-A1 | NOVEL USE | NNMT, NAMPT, NNT | AURKA 4454/4885AURKB 3423/4885AURKC 4170/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.